https://mindmedicinelaw.com/briefing/va-psilocybin-trial-in-alabama-policy-and-clinical-implications-20260904-38672The Psychedelic Journalen2026-09-04T15:07:16.305977+00:00VA Psilocybin Trial in Alabama: Policy and Clinical Implicationsva psilocybin trial, alabama veterans mental health, psychedelic clinical research, federal policy on psychedelics, treatment-resistant ptsd, psychedelic therapy risks, veterans affairs research, conservative state drug policy, psilocybin-assisted therapy, clinical trial diversityhttps://mindmedicinelaw.com/briefing/md-anderson-launches-psilocybin-trial-for-chemotherapy-neurotoxicity-20260904-38673The Psychedelic Journalen2026-09-04T15:06:33.520945+00:00MD Anderson Launches Psilocybin Trial for Chemotherapy Neurotoxicitypsilocybin, chemotherapy-induced neurotoxicity, MD Anderson Cancer Center, clinical trials, oncology supportive care, FDA regulation, psychedelic research, peripheral neuropathy, neuroprotection, drug-drug interactionshttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-therapy-for-severe-ptsd-policy-and-practice-20260904-38670The Psychedelic Journalen2026-09-04T15:06:06.095378+00:00New Zealand Approves MDMA Therapy for Severe PTSD: Policy and Practicemdma approval new zealand, ptsd treatment policy, psychedelic-assisted therapy, medsafe regulation, asia-pacific drug policy, clinical trial data mdma, post-market surveillance, mental health innovationhttps://mindmedicinelaw.com/briefing/silent-synapse-activation-mechanisms-and-clinical-prospects-20260903-38593The Psychedelic Journalen2026-09-04T15:07:55.563945+00:00Silent Synapse Activation: Mechanisms and Clinical Prospectssilent synapse activation, neuroplasticity, depression, addiction, psychedelic research, clinical translation, AMPAR, NMDAR, optogenetics, brain imaginghttps://mindmedicinelaw.com/briefing/psychedelics-ketamine-and-cannabinoids-for-opioid-use-disorder-us-policy-and-cli-20260903-38548The Psychedelic Journalen2026-09-04T15:07:36.541041+00:00Psychedelics, Ketamine, and Cannabinoids for Opioid Use Disorder: US Policy and Clinical Evidence Reviewopioid use disorder, psychedelics, ketamine, cannabinoids, ibogaine, regulatory policy, clinical trials, safety, neuroplasticity, public healthhttps://mindmedicinelaw.com/briefing/donor-surge-reshapes-psychedelic-research-funding-in-us-20260903-38500The Psychedelic Journalen2026-09-03T22:04:23.820111+00:00Donor Surge Reshapes Psychedelic Research Funding in USpsychedelic research funding, FDA approval psychedelics, philanthropy in mental health, clinical trials psychedelics, research infrastructure, donor influence, access models, public health policy, MDMA therapy, US psychedelic policyhttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressive-effects-in-refractory-bipolar-depression-clinical-tria-20260902-38674The Psychedelic Journalen2026-09-04T15:08:14.248430+00:00Ketamine’s Antidepressive Effects in Refractory Bipolar Depression: Clinical Trial Insightsketamine, bipolar depression, treatment-resistant mood disorders, clinical trials, FDA regulation, off-label use, antidepressant mechanisms, psychiatric safety, policy implications, real-world evidencehttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-cocaine-addiction-early-clinical-signals-in-the-u-s-20260902-38502The Psychedelic Journalen2026-09-03T22:04:36.470105+00:00Psilocybin Therapy for Cocaine Addiction: Early Clinical Signals in the U.S.psilocybin therapy, cocaine addiction, clinical trials, psychedelic-assisted therapy, FDA regulation, substance use disorder, public health policy, treatment efficacy, safety riskshttps://mindmedicinelaw.com/briefing/serial-iv-ketamine-for-bipolar-depression-ontario-rct-results-20260902-38253The Psychedelic Journalen2026-09-03T15:04:07.949692+00:00Serial IV Ketamine for Bipolar Depression: Ontario RCT Resultsketamine, bipolar depression, randomized controlled trial, treatment-resistant depression, mania risk, clinical guidelines, health policy, mood stabilizers, psychedelic research, canadahttps://mindmedicinelaw.com/briefing/psychological-mechanisms-in-psychedelic-assisted-therapy-for-suds-2026-scoping-r-20260902-38065The Psychedelic Journalen2026-09-02T22:05:05.000247+00:00Psychological Mechanisms in Psychedelic-Assisted Therapy for SUDs: 2026 Scoping Reviewpsychedelic-assisted therapy, substance use disorders, psychological mechanisms, mystical experiences, clinical trials, integration protocols, FDA, causal mediation, identity transformation, emotional processinghttps://mindmedicinelaw.com/briefing/mapping-human-thalamus-function-seeg-insights-for-psychedelic-research-20260901-38587The Psychedelic Journalen2026-09-04T15:08:31.459207+00:00Mapping Human Thalamus Function: SEEG Insights for Psychedelic Researchthalamus, stereoelectroencephalography, thalamo-cortical circuits, psychedelic research, neuromodulation, clinical trial design, epilepsy, functional brain mapping, direct electrical stimulation, translational neurosciencehttps://mindmedicinelaw.com/briefing/phase-1-results-oral-ketamir-2-safety-and-pk-in-neuropathic-pain-20260901-38588The Psychedelic Journalen2026-09-04T15:06:53.425441+00:00Phase 1 Results: Oral Ketamir-2 Safety and PK in Neuropathic Painketamir-2, nmda antagonist, phase 1 trial, oral formulation, neuropathic pain, safety profile, pharmacokinetics, non-opioid therapeutics, dissociative risk, clinical developmenthttps://mindmedicinelaw.com/briefing/psilocybin-and-neuroplasticity-in-trd-evidence-and-policy-outlook-20260901-38049The Psychedelic Journalen2026-09-03T15:04:18.307449+00:00Psilocybin and Neuroplasticity in TRD: Evidence and Policy Outlookpsilocybin, neuroplasticity, treatment-resistant depression, clinical trials, bdnf, regulatory policy, psychedelic therapy, adverse events, biomarkers, mental healthhttps://mindmedicinelaw.com/briefing/predictors-of-psilocybin-use-intentions-in-us-mental-health-care-20260901-38050The Psychedelic Journalen2026-09-02T22:06:30.862122+00:00Predictors of Psilocybin Use Intentions in US Mental Health Carepsilocybin use intentions, natural vs synthetic psychedelics, mental health treatment, clinical trial recruitment, patient preferences, public health messaging, demographic predictors, FDA approval, psychedelic policy, market accesshttps://mindmedicinelaw.com/briefing/molecular-enriched-fmri-advances-brain-age-prediction-in-neuroscience-20260901-38066The Psychedelic Journalen2026-09-02T22:06:21.163548+00:00Molecular-Enriched fMRI Advances Brain-Age Prediction in Neurosciencemolecular-enriched fMRI, brain-age prediction, neurotransmitter mapping, psychedelic clinical trials, biomarker development, dopamine system, serotonin system, neuroplasticity, MRI harmonization, functional connectivityhttps://mindmedicinelaw.com/briefing/mhcii-mediated-synaptic-pruning-in-dopaminergic-neurons-implications-for-neurode-20260901-38079The Psychedelic Journalen2026-09-02T22:06:12.287934+00:00MHCII-Mediated Synaptic Pruning in Dopaminergic Neurons: Implications for Neurodevelopmental Disordersmhc class ii, dopaminergic neurons, gabaergic synapses, neurodevelopmental disorders, maternal immune activation, synaptic pruning, neuroimmune mechanisms, psychedelic research, synaptic plasticityhttps://mindmedicinelaw.com/briefing/redefining-plasticity-in-psychedelic-neuroscience-research-20260901-38046The Psychedelic Journalen2026-09-02T22:05:53.185027+00:00Redefining 'Plasticity' in Psychedelic Neuroscience Researchpsychedelic therapy, neural plasticity, biomarkers, clinical trial design, regulatory science, mental health outcomes, MR-P framework, mechanistic research, translational neurosciencehttps://mindmedicinelaw.com/briefing/psilocybin-response-in-treatment-resistant-ocd-qualitative-insights-20260901-38048The Psychedelic Journalen2026-09-02T22:05:43.314343+00:00Psilocybin Response in Treatment-Resistant OCD: Qualitative Insightspsilocybin, treatment-resistant ocd, qualitative research, psychological engagement, surrender, self-compassion, emotional processing, clinical trials, therapist training, psychedelic therapyhttps://mindmedicinelaw.com/briefing/era-based-40-hz-assr-biomarkers-in-mood-and-psychotic-disorders-20260901-38088The Psychedelic Journalen2026-09-02T22:05:33.248031+00:00ERA-Based 40-Hz ASSR Biomarkers in Mood and Psychotic Disordersera systems, 40-hz assr, neural synchrony, biomarkers, mood disorders, psychotic disorders, psychedelic trials, precision psychiatry, gamma synchrony, clinical stratificationhttps://mindmedicinelaw.com/briefing/key-brain-circuit-underlies-ketamine-and-antidepressant-response-in-mice-20260901-38089The Psychedelic Journalen2026-09-02T22:05:15.546075+00:00Key Brain Circuit Underlies Ketamine and Antidepressant Response in Miceantidepressant mechanism, ketamine response, neural plasticity, infralimbic cortex, thalamic nucleus reuniens, ventral hippocampus, psychedelic drug development, circuit-based biomarkers, preclinical research, depression neurobiologyhttps://mindmedicinelaw.com/briefing/regulatory-and-methodological-gaps-in-ketamine-psilocybin-trials-20260901-38087The Psychedelic Journalen2026-09-02T22:04:54.239880+00:00Regulatory and Methodological Gaps in Ketamine & Psilocybin Trialsketamine, psilocybin, clinical trial design, regulatory challenges, depression, safety monitoring, participant diversity, informed consent, psychedelic research, policyhttps://mindmedicinelaw.com/briefing/dea-s-federal-rescheduling-questions-implications-for-psychedelics-policy-in-the-20260831-38671The Psychedelic Journalen2026-09-04T15:08:48.408064+00:00DEA’s Federal Rescheduling Questions: Implications for Psychedelics Policy in the U.S.dea marijuana rescheduling, psychedelics policy, federal regulation, controlled substances act, compliance requirements, clinical research, registration process, diversion controls, legal implications, future of psychedelicshttps://mindmedicinelaw.com/briefing/motivation-reward-context-and-control-implications-for-psychedelic-research-20260831-38082The Psychedelic Journalen2026-09-03T15:04:29.193879+00:00Motivation, Reward Context, and Control: Implications for Psychedelic Researchmotivation, controllability, reward context, depression, psychedelic research, behavioral paradigms, clinical trials, effort allocation, drift diffusion modelinghttps://mindmedicinelaw.com/briefing/psychedelics-for-ptsd-depression-clinical-trial-evidence-and-gaps-20260831-38052The Psychedelic Journalen2026-09-02T22:06:03.432841+00:00Psychedelics for PTSD & Depression: Clinical Trial Evidence and Gapspsilocybin, mdma, ptsd, depression, clinical trials, therapist training, safety monitoring, regulatory policy, sample diversity, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/ketamine-induced-memory-dysfunction-mechanisms-and-clinical-policy-implications-20260830-38651The Psychedelic Journalen2026-09-04T15:09:02.451023+00:00Ketamine-Induced Memory Dysfunction: Mechanisms and Clinical Policy Implicationsketamine, memory dysfunction, NMDA receptor, synaptic plasticity, clinical protocols, policy implications, cognitive side effects, psychiatric treatment, regulatory guidancehttps://mindmedicinelaw.com/briefing/systematic-review-of-ketamine-and-esketamine-for-trd-evidence-and-implications-20260830-38100The Psychedelic Journalen2026-09-03T15:04:38.428654+00:00Systematic Review of Ketamine and Esketamine for TRD: Evidence and Implicationsketamine, esketamine, treatment-resistant depression, systematic review, antidepressant efficacy, safety profile, clinical guidelines, regulatory policy, psychedelic research, NMDA receptor